State Street
ACTU

State Street’s Actuate Therapeutics ACTU Stock Holding History

State Street’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.4K Sell
21,850
-44,180
-67% -$102K ﹤0.01% 4096
2026
Q1 		$181K Buy
66,030
+9,740
+17% +$40.4K ﹤0.01% 3906
2025
Q4 		$344K Buy
56,290
+6,395
+13% +$43.9K ﹤0.01% 3776
2025
Q3 		$334K Buy
49,895
+18,481
+59% +$134K ﹤0.01% 3755
2025
Q2 		$192K Buy
+31,414
New +$274K ﹤0.01% 3850

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

State Street's ACTU Position: Q2 2026 in Review

State Street reduced its Actuate Therapeutics (ACTU) stake by 67% in Q2 2026, selling an estimated $102K and leaving 21,850 shares worth $33.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4096.

State Street first reported a position in ACTU in Q2 2025 and has held it in 5 quarters since. The position peaked at $344K in Q4 2025. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • State Street held 21,850 shares of Actuate Therapeutics worth $33.4K as of Q2 2026.
  • State Street sold 44,180 Actuate Therapeutics shares in Q2 2026, an estimated $102K.
  • Actuate Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #4096 holding.
  • State Street first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • State Street's Actuate Therapeutics position peaked at $344K in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.